News Feature
BioCom Spotlight: Adamas Pharmaceuticals CEO, Neil McFarlane
July 17, 2020
Adamas Pharmaceuticals continues to develop solutions to neurological diseases with proven leadership and experienced vision.
Biocom
Read about Adamas in the news, including insights into the work we do, the things we care about, and the milestones we’re working towards
News Feature
July 17, 2020
Adamas Pharmaceuticals continues to develop solutions to neurological diseases with proven leadership and experienced vision.
Biocom
News Feature
June 8, 2020
The U.S. Food and Drug Administration (FDA) has agreed to review Adamas Pharmaceutical’s application asking that oral Gocovri (amantadine) also be approved to treat off episodes in Parkinson’s disease patients using levodopa.
Parkinson’s News Today
News Feature
May 22, 2020
Ranked by Bay Area employees Locally Researched by: Ahalya Srikant, San Francisco Business Times May 22, 2020, 3:00am PDT This List includes biopharmaceutical companies located in the Greater Bay Area, which is defined as Alameda, Contra Costa, Marin, Napa, San Francisco, San Mateo, Santa Clara, Solano and Sonoma counties.
Bizjournal
News Feature
May 13, 2020
The USPTO has issued a new patent to Adamas Pharmaceuticals (ADMS +1.4%) covering a method [Gocovri (amantadine)] of reducing “OFF” time and increasing “ON” time in Parkinson’s disease patients, the second patent it has received covering the reduction of “OFF” time.
Seeking Alpha
News Feature
February 20, 2020
Long-term treatment with Gocovri (amantadine) extended-release capsules was safe and led to sustained reductions in dyskinesia — involuntary, jerky movements — and off episodes in people with Parkinson’s disease, final data from a two-year Phase 3 clinical trial show.
Parkinson’s News Today
News Feature
February 17, 2020
The vice president of Medical Affairs at Adamas Pharmaceuticals discussed the context of these results and what the clinical community should take away from the data from the EASE LID 2 trial of amantadine (Gocovri).
NeurologyLive
News Feature
February 12, 2020
Phase III – Adamas Pharmaceuticals Inc., of Emeryville, Calif. Reported in the Journal of Parkinson’s Disease final results from 2-year open-label study that demonstrated a sustained improvement in levodopa-induced dyskinesia (LID) among patients using Gocovri (amantadine) extended-release capsules; results demonstrated the treatment effect on motor complications was maintained for at least 2 years; median…
Bioworld
News Feature
February 11, 2020
Adamas Pharmaceuticals (NASDAQ:ADMS) has published trial data indicating its Gocovri has maintained its treatment effect on motor complications for at least two years.
Seeking Alpha
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.